×
Anavex Life Sciences Income Taxes 2010-2024 | AVXL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Anavex Life Sciences income taxes from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
View More
Anavex Life Sciences Income Taxes 2010-2024 | AVXL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Anavex Life Sciences income taxes from 2010 to 2024. Income taxes can be defined as the total amount of income tax expense for the given period.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.5B
Vertex Pharmaceuticals (VRTX)
$121.6B
Gilead Sciences (GILD)
$111.4B
Bristol Myers Squibb (BMY)
$110.2B
Regeneron Pharmaceuticals (REGN)
$93B
CSL (CSLLY)
$90B
GSK (GSK)
$76.4B
Argenex SE (ARGX)
$35.6B
Alnylam Pharmaceuticals (ALNY)
$35.3B
BioNTech SE (BNTX)
$26.5B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$23.9B
Moderna (MRNA)
$21B
BeiGene (BGNE)
$19.9B
Genmab (GMAB)
$14.9B
Incyte (INCY)
$14.7B
Exact Sciences (EXAS)
$12.9B
BioMarin Pharmaceutical (BMRN)
$12.7B
Vaxcyte (PCVX)
$12B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.8B
Insmed (INSM)
$11.7B
QIAGEN (QGEN)
$9.8B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.3B
Revolution Medicines (RVMD)
$9.2B
Intra-Cellular Therapies (ITCI)
$9.2B
Roivant Sciences (ROIV)
$8.6B
Viking Therapeutics (VKTX)
$8.1B
Legend Biotech (LEGN)
$8.1B